Effects of Rupatadine on Platelet-Activating Factor–Induced Human Mast Cell Degranulation Compared With Desloratadine and Levocetirizine (The MASPAF Study)

Munoz-Cano R1,2, Ainsua-Enrich E3, Torres-Atencio I4, Martin M3, Sánchez-Lopez J1,2, Bartra J1,2, Picado C1,2,5, Mullol J2,5,6*, Valero A1,2,5*

1Unitat d’Al·lèrgia, Servei de Pneumologia i Al·lèrgia Respiratòria, Hospital Clínic and Universitat de Barcelona, Barcelona, Catalonia, Spain
2Immunoal·lèrgia Respiratòria Clínica i Experimental, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain
3Biochemistry Unit, School of Medicine, Universitat de Barcelona, Barcelona, Catalonia, Spain
4Pharmacology Department, School of Medicine, Universidad de Panamá, Panamá
5Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Barcelona, Catalonia, Spain
6Unitat de Rinologia i Clínica de l’Olfacte, Servei d’Oto-rino-laringologia, Hospital Clínic and Universitat de Barcelona, Barcelona, Catalonia, Spain
*Both authors had similar senior responsibilities

Abstract

Background: Platelet-activating factor (PAF) is a lipid mediator involved in the pathophysiology of several allergic diseases, for example, in the amplification of mast cell (MC) activation in anaphylaxis. Rupatadine is an antihistamine with a demonstrated anti-PAF effect, although its capacity to inhibit PAF-induced MC degranulation has not been fully evaluated.

Objectives: To compare the ability of rupatadine to inhibit PAF-induced MC degranulation with that of desloratadine and levocetirizine and to confirm the dual anti-H1 and anti-PAF activity of rupatadine.

Methods: The human MC line LAD2 and primary MCs (human lung tissue MCs [hLMCs]) were used. MC mediator release was evaluated using the β-hexosaminidase and histamine release assay. The effects of rupatadine (H1 antagonist + PAF receptor antagonist), desloratadine, and levocetirizine (H1 antagonists) on LAD2 and hLMCs were compared. The PAF receptor antagonists WEB2086, BN52021, and CV6209 were also tested. PAF receptor protein expression was evaluated in both LAD2 and hLMCs.

Results: CV6209 and rupatadine inhibited PAF-induced MC degranulation in both LAD2 and hLMCs. In LAD2, rupatadine (5 and 10 µM) and levocetirizine (5 µM), but not desloratadine, inhibited PAF-induced β-hexosaminidase release. Rupatadine (1-10 µM), levocetirizine (1-10 µM), and desloratadine (10 µM) inhibited PAF-induced histamine release. Rupatadine at 10 µM had an inhibitory effect on hLMC degranulation, but levocetirizine and desloratadine did not.

Conclusions: This study shows that rupatadine and, to a lesser extent, levocetirizine, but not desloratadine, inhibit PAF-induced degranulation in both LAD2 and hLMCs. These findings support the dual antihistamine and anti-PAF effect of rupatadine in allergic disorders.

Introduction

Platelet-activating factor (PAF) is a lipid mediator released by many cells, including mast cells and eosinophils [1], which are implicated in allergic diseases such as asthma, allergic rhinitis, and anaphylaxis [2-4]. There is evidence that PAF can activate human lung mast cells (hLMCs), but not skin mast cells, through PAF receptor and phospholipase C-γ1 and -β2 [5]. These findings provide a plausible mechanism whereby PAF mediates an amplification loop for mast cell activation in the human mast cell line LAD2. PAF-induced mast cell degranulation is partially dependent on extracellular calcium, as demonstrated in human peripheral blood-derived mast cells [5]. No studies have been performed to date on the human mast cell line LAD2. PAF-induced mast cell degranulation is partially dependent on extracellular calcium, as demonstrated in human peripheral blood-derived mast cells [5] and in the human leukemia mast cell line HMC-1 [13].

Despite the significant relevance of PAF in the pathophysiology of allergic diseases, studies of PAF antagonists to date have failed to show a definitive and positive effect on bronchial symptoms [2,14]. Moreover, there are no studies with selective PAF antagonists in human rhinitis or anaphylaxis. Lack of evidence of the clinical efficacy of PAF antagonists probably accounts for their absence in the current armamentarium of allergic airway disease and the restriction of their use to research.

Rupatadine is an H1 receptor antagonist indicated for the treatment of allergic rhinitis [15] and urticaria [16]. It has the properties of an ideal second-generation antihistamine, including anti-allergic/anti-inflammatory effects such as inhibition of cytokine secretion [8,17]. In addition, the antagonistic effect of rupatadine on the PAF receptor has been demonstrated in in vitro studies and in a wide series of in vivo pharmacological studies based on both animals and humans [18]. The clinical anti-PAF effect of rupatadine was recently demonstrated using an in vivo human nasal provocation test with PAF [9,10]. However, the mechanism of action of the anti-PAF effect of rupatadine has not been fully evaluated in human mast cells [17,19].

The objective of the MASPFAF study was to investigate the ability of rupatadine to inhibit PAF-induced mast cell degranulation. To confirm its anti-H1 and anti-PAF dual effect, rupatadine was compared with selective anti-PAF antagonists and second-generation antihistamines (desloratadine and levocetirizine) with unknown PAF antagonist activity.

Material and Methods

Reagents

PAF, desloratadine, WEB2086, and BN52021 were purchased from Sigma-Aldrich. CV6209 was purchased from Enzo Life Sciences. Rupatadine and levocetirizine were provided by Grupo Uriach SA.
Mast cell degranulation was evaluated using both β-hexosaminidase and histamine assays in LAD2 cells. First, time-course and dose-response assays were performed in order to determine the optimal dose and incubation time. PAF was tested at 1 μM for 15 and 30 minutes and at 10 μM for 5, 15, and 30 minutes. Second, mast cells were preincubated with antihistamines or anti-PAF for 30 minutes and then triggered with PAF 10 μM for 30 minutes. Rupatadine (1 μM, with PAF 10 μM for 30 minutes (optimal dose and incubation time) for the degranulation assays. Rupatadine (1 μM, with PAF 10 μM for 30 minutes (optimal dose and incubation time) for the degranulation assays. Mast cell degranulation was evaluated in LAD2 owing to the limited availability of hLMCs. Desloratadine and levocetirizine, neither of which has a demonstrated anti-PAF effect, have been used to evaluate the differential anti-PAF effects of rupatadine. Conversely, CV6209, WEB2086, and BN52021 are PAF antagonists with a demonstrated inhibitory effect [5,21,22].

Mast cell degranulation was evaluated using both β-hexosaminidase and histamine assays in LAD2 cells. First, time-course and dose-response assays were performed in order to determine the optimal dose and incubation time. PAF was tested at 1 μM for 15 and 30 minutes and at 10 μM for 5, 15, and 30 minutes. Second, mast cells were preincubated with antihistamines or anti-PAF for 30 minutes and then triggered with PAF 10 μM for 30 minutes (optimal dose and incubation time) for the degranulation assays. Rupatadine (1 μM, 5 μM, and 10 μM), desloratadine (1 μM, 5 μM, and 10 μM), levocetirizine (1 μM, 5 μM, and 10 μM), CV6209 (0.2 μM and 2 μM), WEB2086 (1 μM, 10 μM, and 100 μM), and BN52021 (1 μM, 10 μM, and 100 μM) were tested. In order to determine the relationship between PAF-induced mast cell degranulation and calcium mobilization, several doses of PAF were tested (1 μM, 10 μM, and 50 μM) in LAD-2 calcium assays. Mast cell degranulation was evaluated in hLMCs using histamine assays only. Mast cells were preincubated with antihistamines or anti-PAF for 30 minutes and then triggered with PAF 10 μM for 30 minutes. Rupatadine, desloratadine, and levocetirizine were tested at 10 μM because it was the only concentration that inhibited PAF-induced histamine release in LAD2. CV6209 was tested at 2 μM and was the only anti-PAF antagonist used for these experiments owing to the lack of an inhibitory effect of BN52021 and WEB2086 in LAD-2 (data not shown).

PAF receptor expression was evaluated in mast cells from both LAD2 and hLMCs.

Study Design

Most of the experiments were performed in LAD2 owing to the limited availability of hLMCs. Desloratadine and levocetirizine, neither of which has a demonstrated anti-PAF effect, have been used to evaluate the differential anti-PAF effects of rupatadine. Conversely, CV6209, WEB2086, and BN52021 are PAF antagonists with a demonstrated inhibitory effect [5,21,22].

Mast cell degranulation was evaluated using both β-hexosaminidase and histamine assays in LAD2 cells. First, time-course and dose-response assays were performed in order to determine the optimal dose and incubation time. PAF was tested at 1 μM for 15 and 30 minutes and at 10 μM for 5, 15, and 30 minutes. Second, mast cells were preincubated with antihistamines or anti-PAF for 30 minutes and then triggered with PAF 10 μM for 30 minutes (optimal dose and incubation time) for the degranulation assays. Rupatadine (1 μM, 5 μM, and 10 μM), desloratadine (1 μM, 5 μM, and 10 μM), levocetirizine (1 μM, 5 μM, and 10 μM), CV6209 (0.2 μM and 2 μM), WEB2086 (1 μM, 10 μM, and 100 μM), and BN52021 (1 μM, 10 μM, and 100 μM) were tested. In order to determine the relationship between PAF-induced mast cell degranulation and calcium mobilization, several doses of PAF were tested (1 μM, 10 μM, and 50 μM) in LAD-2 calcium assays. Mast cell degranulation was evaluated in hLMCs using histamine assays only. Mast cells were preincubated with antihistamines or anti-PAF for 30 minutes and then triggered with PAF 10 μM for 30 minutes. Rupatadine, desloratadine, and levocetirizine were tested at 10 μM because it was the only concentration that inhibited PAF-induced histamine release in LAD2. CV6209 was tested at 2 μM and was the only anti-PAF antagonist used for these experiments owing to the lack of an inhibitory effect of BN52021 and WEB2086 in LAD-2 (data not shown).

PAF receptor expression was evaluated in mast cells from both LAD2 and hLMCs.
Rupatadine Inhibits PAF-Induced Mast Cell Degranulation

Effect of PAF Antagonists on PAF-Induced Mast Cell Degranulation

In LAD2, CV6209 inhibited PAF-induced β-hexosaminidase release at 0.2 µM (45%, P<.01) and 2 µM (56%, P<.001) (Figure 2A) and histamine release at 2 µM (30%, P<.01) (Figure 2B). WEB2086 and BN52021 did not inhibit PAF-induced release of mast cells in LAD2 or in hLMCs (data not shown).

In hLMCs, CV6209 at 2 µM inhibited PAF-induced histamine release (24%, P<.01) (Figure 2C).

Effect of Rupatadine, Levocetirizine, and Desloratadine on PAF-Induced Mast Cell Degranulation

β-hexosaminidase release in LAD2. Only rupatadine 10 µM (48%) significantly (P<.01) inhibited PAF-induced β-hexosaminidase release. No statistical differences were found with rupatadine 5 µM (30%), 25 µM (34%), or 100 µM (no inhibition) or with levocetirizine from 1 µM to 100 µM (Figure 3A and 3B, respectively). Desloratadine did not show any inhibitory effect at the concentrations tested (Figure 3C).
Histamine release in LAD2. Rupatadine 5 µM (29%) and 10 µM (30%) and levocetirizine 5 µM (25%), 10 µM (27%), and 25 µM (25%) significantly inhibited PAF-induced histamine release (P<.01) (Figure 4A and 4B). Desloratadine did not significantly inhibit histamine release at any of the concentrations tested (Figure 4C).

Histamine release in hLMCs. Rupatadine 10 µM (12%) significantly (P<.01) inhibited PAF-induced histamine release, but this effect was not observed with either desloratadine (2%) or levocetirizine (4%) (Figure 5).

**Discussion**

LAD2 is one of 3 well-established human mast cell lines and usually serves as a replacement for mast cells in mature tissue [24]. PAF receptor expression has been demonstrated in several cell types, including platelets, eosinophils, and hLMCs [25-27], but never in LAD2. In our study, we demonstrated for the first time the presence of the PAF receptor in LAD2. We also confirmed that the PAF receptor is present in hLMCs [5].
Rupatadine Inhibits PAF-Induced Mast Cell Degranulation


© 2017 Esmon Publicidad

doi: 10.18176/jiaci.0117

In our model, the inhibitory effect demonstrated by PAF-specific antagonists such as CV6209 suggests that the PAF effect in our model may be mediated by PAF receptor activation. This is consistent with previous studies showing that the inhibitory effect of rupatadine was comparable to that of PAF antagonists such as CV6209 on LAD2 and hLMCs, consistent with the hypothesis that CV6209 inhibits PAF-induced histamine release in human peripheral blood-derived mast cells, although it has never been compared with rupatadine [5]. Our results showed that lower concentrations of PAF would not activate the PAF receptor in LAD2.

In our study, CV6209 inhibited PAF-induced histamine and β-hexosaminidase release in both LAD2 and hLMCs. However, the PAF antagonists BN52021 and WEB2086 had no inhibitory effect (data not shown). Although several studies have compared rupatadine with WEB2086 and BN52021 and demonstrated a greater effect of these PAF antagonists on PAF-induced mortality in mice or platelet aggregation in rabbits and human samples [18], their effect on mast cells has never been evaluated. On the other hand, it has been demonstrated that CV6209 inhibits PAF-induced histamine release in human peripheral blood-derived mast cells, although it has never been compared with rupatadine [5]. Our results showed that the inhibitory effect of rupatadine was comparable to that of CV6209 on LAD2, although the effect of CV6209 on hLMCs was greater than that of rupatadine.

In the present study, we demonstrated that rupatadine and, to a lesser extent, levocetirizine inhibited PAF-induced human mast cell degranulation and suggest that this effect could be mediated through the PAF receptor. Desloratadine, an antihistamine with no anti-PAF effect, failed to show any consistent inhibitory effect.

In addition to mast cell degranulation, our study also confirmed the ability of PAF to mobilize intracellular calcium, as previously demonstrated by other authors [5,13]. This evidence and the inhibitory effect demonstrated by PAF-specific antagonists such as CV6209 suggest that the PAF effect in our model may be mediated by PAF receptor activation.

Kajiwara et al [5] recently demonstrated the activation of human mast cells through the PAF receptor, reaching 20%-30% of total histamine release in hLMCs at a concentration as low as 1 nM [5]. The concentration used in our study was higher (10 μM) than that used in the study by Kajiwara et al, probably owing to differences in the cell types used (LAD2 and hLMCs vs mast cells from peripheral blood-derived progenitors) and the high interindividual sensitivity in response to PAF stimulation observed in hLMCs. Our findings differ from those of Alevizos et al [19], who used LAD2 stimulated with PAF. Although histamine release was induced with a PAF concentration as low as 0.01 μM, β-hexosaminidase release could not be induced at that dose. In our study, PAF 10 μM induced both histamine and β-hexosaminidase release with no impact on cell viability. Moreover, we were unable to demonstrate mobilization of calcium with PAF concentrations below 10 μM, suggesting that lower concentrations of PAF would not activate the PAF receptor in LAD2.

Figure 4. Effect of second-generation antihistamines on PAF-induced histamine release in the LAD2 cell line. Rupatadine (A) and levocetirizine (B), and to a lesser extent desloratadine (C), inhibit histamine release. Results are expressed as mean (SD) of 3 independent experiments. ***P<.001 compared with controls. †† P<.01 and †P<.05 compared with PAF. PAF indicates platelet-activating factor; Histamine (%), histamine release rate.

Figure 5. Effect of second-generation antihistamines on PAF-induced histamine release in primary human lung mast cells. Rupatadine, but not levocetirizine or desloratadine, inhibits histamine release. Results are expressed as mean (SD) of 3 independent experiments. ***P<.001 compared with controls. †† P<.01 compared with PAF. PAF indicates platelet-activating factor; Histamine (%), histamine release rate.
In one of the few studies investigating the role of rupatadine in mast cells, Alvezios et al [19] compared the effect of rupatadine and diphenhydramine on PAF-induced histamine and cytokine release in LAD2. The discrepancies in the effect of rupatadine observed in our study and that of Alvezios et al could be related to differences in the PAF concentrations used. We used a significantly higher dose of PAF (10 μM) as a degranulation trigger and found that rupatadine was capable of inhibiting PAF-induced degranulation in a range that runs from 1 μM to 10 μM. Surprisingly, despite using a 10-fold lower concentration of PAF, Alvezios et al showed that only rupatadine at 25 μM had a significant inhibitory effect. Furthermore, both H1 receptor antagonists—diphenhydramine in the study by Alvezios et al and desloratadine in ours—had no inhibitory effect on PAF-induced histamine or cytokine production, suggesting a lack of anti-PAF effect. Other previous studies performed with rupatadine in human mast cells, specifically in cord blood mast cells, have shown that rupatadine 25 μM inhibited IgE-mediated release of TNF-α and cytokines (IL-6, IL-8, IL-10, and IL-13) [17]. In HMC-1 and LAD2, rupatadine 10 μM to 50 μM inhibited cytokine release induced by substance P, with no impact on cell viability at any concentration [17].

The present study also showed that desloratadine had no inhibitory effect and that levocetirizine inhibited PAF-induced degranulation of LAD2 at some concentrations but not in hLMCs. However, Weller et al [28] demonstrated that desloratadine 1 μM was able to inhibit histamine release in isolated human skin mast cells. Queralt et al [29] reported a similar effect for loratadine and rupatadine in canine mast cells and HMC-1 after stimulation with the calcium ionophore A23187, Con A, and anti-IgE. However, in our study, desloratadine, a metabolite of loratadine, showed no inhibitory effect during stimulation with PAF in LAD2 and hLMCs. The different mast cell phenotype observed in human skin and human lung [30,31], as well as the different trigger used (anti-IgE, calcium ionophore, Con A, and substance P) [28], could account for this discrepancy [32]. Although desloratadine, a second-generation antihistamine, has been shown to have some antiallergic effects [33] and to be up to 10 times more potent than loratadine in antagonizing histamine-induced increases in nasal microvascular permeability [34], in the light of our findings it lacks an anti-PAF effect.

To our knowledge, no studies have examined levocetirizine in mast cells. As a second-generation antihistamine, some antiallergic effects have been reported [35], although none of them are related to PAF. However, albeit to a lesser extent than rupatadine, levocetirizine inhibited PAF-mediated LAD2 degranulation (mainly histamine release at several concentrations), a finding that also suggests potential anti-PAF activity in LAD2 but not in primary hLMCs.

Of note, the concentration of antihistamine necessary to decrease mast cell activation in vitro in our study may be higher than that necessary in vivo. Single cell models are partially representative of what is happening in a whole organism (a human being), and the role of metabolic pathways present in the in vivo model is neglected in in vitro (cell-based) studies. Furthermore, the cell culture environment does not exactly reproduce in vivo conditions. Therefore, our study must be considered an in vitro model for investigation of the effect of the drug on mast cell activation/mediator release, although the concentrations used are not useful as a reference for doses in treatment (an in vivo dose search is always mandatory).

Finally, the strongest inhibitory effect of rupatadine in PAF-induced mast cell degranulation from both LAD2 and hLMCs clearly correlates with its clinical effect in allergic rhinitis [10], where rupatadine, but not levocetirizine, showed an inhibitory effect (reduced total nasal symptoms score).

In conclusion, we demonstrated that rupatadine and—albeit to a lesser extent—levocetirizine have anti-PAF activity in human mast cells. The dual antihistamine and anti-PAF activity of rupatadine may provide the drug with greater anti-inflammatory/antiallergic activity, as reported elsewhere [10].

Acknowledgments

We thank Maria Perez for technical support.

Funding

This study was supported by a Sociedad Española de Allergia e Immunología Clínica (SEAIINC) grant, Ministerio de Economía y Competitividad-Carlos III Health Institute (FIS-PI09/1202), Spain and Grupo Uriach SA, Barcelona, Spain. RM-C was the recipient of the “Río Hortega” Fellowship, Ministerio de Economía y Competitividad, Carlos III Health Institute, Spain.

Conflicts of Interest

JM is or has been a member of national and international scientific advisory boards (consulting) and has received fees for lectures and grants for research projects from ALK-Abelló, Boheringer-Ingelheim, Crucell, Esteve, FAES, GSK, Hartington Pharmaceuticals, Johnson & Johnson, MEDA Pharma, MSD, Novartis, Pierre Fabre, Sanofi-Aventis, Schering Plough, UCB, and Uriach Group. AV is or has been member of national scientific advisory Boards (consulting), received fees for lectures and grants for research projects from Boheringer-Ingelheim, Esteve, FAES, GSK, Chiesi, MEDA Pharma, MSD, Novartis, Leti, Stallergenes, Sanofi-Aventis, Orion Pharma, Vifor, UCB, and Uriach Group. CB has been or is a member of national and international scientific advisory boards (consulting) and has received lecture fees and grants for research projects from Esteve, FAES, MSD, Novartis, Chiesi, Grupo Uriach, and GSK. JB is or has been a member of national scientific advisory boards (consulting) and received fees for lectures from FAES, UCB, Grupo Uriach and Hall Allergy. RM-C, CA-E, IT-A, MM, and JS declare that they have no conflicts of interest.

Previous Presentations

This study was presented in part as a poster at the Annual Meeting of the American Academy of Asthma, Allergy and Immunology (AAAIAI) in New Orleans, United States of America, February 2012.

References

Rupatadine Inhibits PAF-Induced Mast Cell Degranulation


35. Walsh GM. The anti-inflammatory effects of levocetirizine--are they clinically relevant or just an interesting additional effect? Allergy Asthma Clin Immunol. 2009;5:14.

Rosa Muñoz-Cano
Unitat d’Al·lèrgia. Servei de Pneumologia i Al·lèrgia Respiratòria
Hospital Clinic, IDIBAPS
Villarroel 170
Barcelona 08036
Catalonia, Spain
E-mail: rmunoz@clinic.ub.es